Human African Trypanosomiasis Research

 

  • Target disease: HAT
  • Partners (since project start): TB Alliance, USA; University of Auckland, New Zealand; SCYNEXIS Inc., USA; Pace University, USA; Wuxi AppTech, China
  • Project start: June 2011
  • Funding (since project start): Department for International Development (DFID), UK;  Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany;  Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.
  • Project status: Completed

 

  • Overall Objective: Progress a backup nitroimidazole into pre-clinical development

 

The nitroimidazole backup programme for HAT identified SCYX-2035811 as a suitable candidate for further exploration, and although initial results in animal models had shown excellent activity, further studies showed the doses tested to give insufficient cure. Given the progress of fexinidazole (Phase II/ III) and SCYX-7158 (Phase I), further development was put on hold in 2013, and the project has now been stopped.


Last update: August 2015